Review



polyclonal dusp4 mkp 2 antibody  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Novus Biologicals polyclonal dusp4 mkp 2 antibody
    Phosphatases differentially expressed in clinical ER − ERBB2 + versus triple-negative (TN) BC patients in this series (Agilent platform) and in GSE20194 (Affymetrix platform) (both FDR q-value <0.05).
    Polyclonal Dusp4 Mkp 2 Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal dusp4 mkp 2 antibody/product/Novus Biologicals
    Average 90 stars, based on 1 article reviews
    polyclonal dusp4 mkp 2 antibody - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers"

    Article Title: Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers

    Journal: International Journal of Oncology

    doi: 10.3892/ijo.2014.2648

    Phosphatases differentially expressed in clinical ER − ERBB2 + versus triple-negative (TN) BC patients in this series (Agilent platform) and in GSE20194 (Affymetrix platform) (both FDR q-value <0.05).
    Figure Legend Snippet: Phosphatases differentially expressed in clinical ER − ERBB2 + versus triple-negative (TN) BC patients in this series (Agilent platform) and in GSE20194 (Affymetrix platform) (both FDR q-value <0.05).

    Techniques Used:

    Phosphatases differentially expressed between the molecular ER − ERBB2 + and the basal-like enriched BC in this series (FDR q-value <0.05) and in the NKI series (FDR q-value ≤0.01).
    Figure Legend Snippet: Phosphatases differentially expressed between the molecular ER − ERBB2 + and the basal-like enriched BC in this series (FDR q-value <0.05) and in the NKI series (FDR q-value ≤0.01).

    Techniques Used:

    Phosphatases differentially expressed between ER + and ER − BC in common among GSE7390, GSE20194 and GSE2034 (FDR q-value ≤0.05).
    Figure Legend Snippet: Phosphatases differentially expressed between ER + and ER − BC in common among GSE7390, GSE20194 and GSE2034 (FDR q-value ≤0.05).

    Techniques Used:

    Co-expression network analysis from the GeneMania server using DUSP4, DUSP6 and DUSP10 as query genes.
    Figure Legend Snippet: Co-expression network analysis from the GeneMania server using DUSP4, DUSP6 and DUSP10 as query genes.

    Techniques Used: Expressing

    DUSP4, DUSP6 and phospo-ERK1/2 immuohistochemical percentage scores within the triple-negative breast carcinomas and the ERBB2-positive, ER and PR-negative breast carcinoma groups.
    Figure Legend Snippet: DUSP4, DUSP6 and phospo-ERK1/2 immuohistochemical percentage scores within the triple-negative breast carcinomas and the ERBB2-positive, ER and PR-negative breast carcinoma groups.

    Techniques Used: Expressing, Two Tailed Test

    Multiphosphatase signature comprising 58 probes (48 genes) trained in GSE2034 training set and validated in GSE7390 (both Affymetrix HGU133A platform).
    Figure Legend Snippet: Multiphosphatase signature comprising 58 probes (48 genes) trained in GSE2034 training set and validated in GSE7390 (both Affymetrix HGU133A platform).

    Techniques Used:



    Similar Products

    polyclonal dusp4 mkp 2 antibody  (Novus Biologicals)
    90
    Novus Biologicals polyclonal dusp4 mkp 2 antibody
    Phosphatases differentially expressed in clinical ER − ERBB2 + versus triple-negative (TN) BC patients in this series (Agilent platform) and in GSE20194 (Affymetrix platform) (both FDR q-value <0.05).
    Polyclonal Dusp4 Mkp 2 Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal dusp4 mkp 2 antibody/product/Novus Biologicals
    Average 90 stars, based on 1 article reviews
    polyclonal dusp4 mkp 2 antibody - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Phosphatases differentially expressed in clinical ER − ERBB2 + versus triple-negative (TN) BC patients in this series (Agilent platform) and in GSE20194 (Affymetrix platform) (both FDR q-value <0.05).

    Journal: International Journal of Oncology

    Article Title: Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers

    doi: 10.3892/ijo.2014.2648

    Figure Lengend Snippet: Phosphatases differentially expressed in clinical ER − ERBB2 + versus triple-negative (TN) BC patients in this series (Agilent platform) and in GSE20194 (Affymetrix platform) (both FDR q-value <0.05).

    Article Snippet: The antibodies used were the rabbit polyclonal antibodies specific against the dual phosphorylated form of ERK1/2 (Thr202/Tyr204) (#4370, Cell Signaling, Beverly, MA, USA) at a dilution of 1:200, the polyclonal DUSP4 (MKP-2) antibody (NBP1-19592, Novus Biologicals, Littleton, CO, USA) at a dilution of 1:100, and a goat polyclonal anti-DUSP6 antibody (MKP-3) (sc-8599, Santa Cruz Biotechnology Lab Inc., Santa Cruz, CA, USA) at a dilution of 1:100, in the last case the anti-goat IG (HRP) (NB710-H, Novus Biologicals) was used as a secondary antibody at a dilution of 1:400.

    Techniques:

    Phosphatases differentially expressed between the molecular ER − ERBB2 + and the basal-like enriched BC in this series (FDR q-value <0.05) and in the NKI series (FDR q-value ≤0.01).

    Journal: International Journal of Oncology

    Article Title: Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers

    doi: 10.3892/ijo.2014.2648

    Figure Lengend Snippet: Phosphatases differentially expressed between the molecular ER − ERBB2 + and the basal-like enriched BC in this series (FDR q-value <0.05) and in the NKI series (FDR q-value ≤0.01).

    Article Snippet: The antibodies used were the rabbit polyclonal antibodies specific against the dual phosphorylated form of ERK1/2 (Thr202/Tyr204) (#4370, Cell Signaling, Beverly, MA, USA) at a dilution of 1:200, the polyclonal DUSP4 (MKP-2) antibody (NBP1-19592, Novus Biologicals, Littleton, CO, USA) at a dilution of 1:100, and a goat polyclonal anti-DUSP6 antibody (MKP-3) (sc-8599, Santa Cruz Biotechnology Lab Inc., Santa Cruz, CA, USA) at a dilution of 1:100, in the last case the anti-goat IG (HRP) (NB710-H, Novus Biologicals) was used as a secondary antibody at a dilution of 1:400.

    Techniques:

    Phosphatases differentially expressed between ER + and ER − BC in common among GSE7390, GSE20194 and GSE2034 (FDR q-value ≤0.05).

    Journal: International Journal of Oncology

    Article Title: Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers

    doi: 10.3892/ijo.2014.2648

    Figure Lengend Snippet: Phosphatases differentially expressed between ER + and ER − BC in common among GSE7390, GSE20194 and GSE2034 (FDR q-value ≤0.05).

    Article Snippet: The antibodies used were the rabbit polyclonal antibodies specific against the dual phosphorylated form of ERK1/2 (Thr202/Tyr204) (#4370, Cell Signaling, Beverly, MA, USA) at a dilution of 1:200, the polyclonal DUSP4 (MKP-2) antibody (NBP1-19592, Novus Biologicals, Littleton, CO, USA) at a dilution of 1:100, and a goat polyclonal anti-DUSP6 antibody (MKP-3) (sc-8599, Santa Cruz Biotechnology Lab Inc., Santa Cruz, CA, USA) at a dilution of 1:100, in the last case the anti-goat IG (HRP) (NB710-H, Novus Biologicals) was used as a secondary antibody at a dilution of 1:400.

    Techniques:

    Co-expression network analysis from the GeneMania server using DUSP4, DUSP6 and DUSP10 as query genes.

    Journal: International Journal of Oncology

    Article Title: Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers

    doi: 10.3892/ijo.2014.2648

    Figure Lengend Snippet: Co-expression network analysis from the GeneMania server using DUSP4, DUSP6 and DUSP10 as query genes.

    Article Snippet: The antibodies used were the rabbit polyclonal antibodies specific against the dual phosphorylated form of ERK1/2 (Thr202/Tyr204) (#4370, Cell Signaling, Beverly, MA, USA) at a dilution of 1:200, the polyclonal DUSP4 (MKP-2) antibody (NBP1-19592, Novus Biologicals, Littleton, CO, USA) at a dilution of 1:100, and a goat polyclonal anti-DUSP6 antibody (MKP-3) (sc-8599, Santa Cruz Biotechnology Lab Inc., Santa Cruz, CA, USA) at a dilution of 1:100, in the last case the anti-goat IG (HRP) (NB710-H, Novus Biologicals) was used as a secondary antibody at a dilution of 1:400.

    Techniques: Expressing

    DUSP4, DUSP6 and phospo-ERK1/2 immuohistochemical percentage scores within the triple-negative breast carcinomas and the ERBB2-positive, ER and PR-negative breast carcinoma groups.

    Journal: International Journal of Oncology

    Article Title: Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers

    doi: 10.3892/ijo.2014.2648

    Figure Lengend Snippet: DUSP4, DUSP6 and phospo-ERK1/2 immuohistochemical percentage scores within the triple-negative breast carcinomas and the ERBB2-positive, ER and PR-negative breast carcinoma groups.

    Article Snippet: The antibodies used were the rabbit polyclonal antibodies specific against the dual phosphorylated form of ERK1/2 (Thr202/Tyr204) (#4370, Cell Signaling, Beverly, MA, USA) at a dilution of 1:200, the polyclonal DUSP4 (MKP-2) antibody (NBP1-19592, Novus Biologicals, Littleton, CO, USA) at a dilution of 1:100, and a goat polyclonal anti-DUSP6 antibody (MKP-3) (sc-8599, Santa Cruz Biotechnology Lab Inc., Santa Cruz, CA, USA) at a dilution of 1:100, in the last case the anti-goat IG (HRP) (NB710-H, Novus Biologicals) was used as a secondary antibody at a dilution of 1:400.

    Techniques: Expressing, Two Tailed Test

    Multiphosphatase signature comprising 58 probes (48 genes) trained in GSE2034 training set and validated in GSE7390 (both Affymetrix HGU133A platform).

    Journal: International Journal of Oncology

    Article Title: Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers

    doi: 10.3892/ijo.2014.2648

    Figure Lengend Snippet: Multiphosphatase signature comprising 58 probes (48 genes) trained in GSE2034 training set and validated in GSE7390 (both Affymetrix HGU133A platform).

    Article Snippet: The antibodies used were the rabbit polyclonal antibodies specific against the dual phosphorylated form of ERK1/2 (Thr202/Tyr204) (#4370, Cell Signaling, Beverly, MA, USA) at a dilution of 1:200, the polyclonal DUSP4 (MKP-2) antibody (NBP1-19592, Novus Biologicals, Littleton, CO, USA) at a dilution of 1:100, and a goat polyclonal anti-DUSP6 antibody (MKP-3) (sc-8599, Santa Cruz Biotechnology Lab Inc., Santa Cruz, CA, USA) at a dilution of 1:100, in the last case the anti-goat IG (HRP) (NB710-H, Novus Biologicals) was used as a secondary antibody at a dilution of 1:400.

    Techniques: